Effect of dendritic cell vaccine against a tongue squamous cell cancer cell line (Tca8113) in vivo and in vitro

International Journal of Oral and Maxillofacial Surgery

Volumn 35, Issue 6, 2006, Pages 544-550

  Wang, Z ^a   Hu, Q ^a   Han, W ^a   Hua, Z ^a   Tian, W ^b   Huang, X ^a   Li, S ^b  

^a NANJING UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

dendritic cell; oral squamous cell carcinoma; Tca8113 cell; tumour immunotherapy; tumour vaccine

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CANCER VACCINE; DRUG VEHICLE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 4; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER GRAFT; CANCER IMMUNIZATION; CANCER INHIBITION; CELL COUNT; CELL CULTURE; CELL KILLING; CELL LYSATE; CELL STIMULATION; CELLULAR IMMUNITY; CONTROLLED STUDY; DENDRITIC CELL; DRUG EFFECT; DRUG FORMULATION; FREEZE THAWING; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; NUDE MOUSE; PERIPHERAL BLOOD MONONUCLEAR CELL; SQUAMOUS CELL CARCINOMA; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TONGUE CANCER; TUMOR GROWTH;

ANIMALS; CANCER VACCINES; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; COLORING AGENTS; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOPHENOTYPING; INTERLEUKIN-4; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; T-LYMPHOCYTES; TETRAZOLIUM SALTS; THIAZOLES; TONGUE NEOPLASMS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33646517063     PISSN: 09015027     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijom.2005.11.004     Document Type: Article

References (25)

1. Albert M.L., Sauter B., and Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 392 (1998) 86-89
2. Ashley D.M., Faiola B., Nair S., Hale L.P., Bigner D.D., and Gilboa E. Bone marrow-generated dendritic cells pulsed with tumour extracts or tumour RNA induce antitumour immunity against central nervous system tumours. J Exp Med 186 (1997) 1177-1182
3. Banchereau J., and Steinman R.M. Dendritic cells and the control of immunity. Nature 392 (1998) 245-252
4. Boczkowski D., Nair Sk, Snyder D., and Gilboa E. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med. 184 (1996) 465-472
5. Celluzzi C.M., and Falo Jr. L.D. Physical interaction between dendritic cells and tumour cells results in an immunogen that induces protective and therapeutic tumour rejection. J Immunol 160 (1998) 3081-3085
6. Garrity T., Pandit R., Wright M.A., Benefield J., Keni S., and Young M.R. Increased presence of CD34 + cells in the peripheral blood of head and neck cancer patients and their differentiation into dendritic cells. Int J Cancer 73 (1997) 663-669
7. Goldman S.A., Baker E., Weyant R.J., Clarke M.R., Myers J.N., and Lotze M.T. Peritumoural CD1a-positive dendritic cells are associated with improved survival in patients with tongue carcinoma. Arch Otolaryngol Head Neck Surg 124 (1998) 641-646
8. Gong J., Chen D., Kashiwaba M., and Kufe D. Induction of antitumour activity by immunization with fusions of dendritic and carcinoma cells. Nat Med 3 (1997) 558-561
9. Herr W., Ranieri E., Olson W., Zarour H., Gesualdo L., and Storkus W.J. Mature dendritic cells pulsed with freeze-thaw cell lysates define an effective in vitro vaccine designed to elicit EBV-specific CD4(+) and CD8(+) T lymphocyte responses. Blood 96 (2000) 1857-1864
10. Holtl L., Zelle-Rieser C., Gander H., Papesh C., Ramoner R., Bartsch G., Rogatsch H., Barsoum A.L., Coggin Jr. J.H., and Thurnher M. Immunotherapy of metastatic renal cell carcinoma with tumour lysate-pulsed autologous dendritic cells. Clin Cancer Res 8 (2002) 3369-3376
11. Kasinrerk W., Baumruker T., Majdic O., Knapp W., and Stockinger H. CD1 molecule expression on human monocytes induced by granulocyte-macrophage colony-stimulating factor. J Immunol 150 (1993) 579-584
12. Kono K., Takahashi A., Sugai H., Fujii H., Choudhury A.R., Kiessling R., and Matsumoto Y. Dendritic cells pulsed with HER-2/neu-derived peptides can induce specific T-cell responses in patients with gastric cancer. Clin Cancer Res 8 (2002) 3394-3400
13. Kugler A., Stuhler G., Walden P., Zoller G., Zobywalski A., Brossart P., Trefzer U., Ullrich S., Muller C.A., Becker V., Gross A.J., Hemmerlein B., Kanz L., Muller G.A., and Ringert R.H. Regression of human metastatic renal cell carcinoma after vaccination with tumour cell-dendritic cell hybrids. Nat Med 6 (2000) 332-336
14. Kurokawa H., Tsuru S., Okada M., Nakamura T., and Kajiyama M. Evaluation of tumour markers in patients with squamous cell carcinoma in the oral cavity. Int J Oral Maxillofac Surg 22 (1993) 35-38
15. Nair S.K., Boczkowski D., Morse M., Cumming R.I., Lyerly H.K., and Gilboa E. Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA. Nat Biotechnol 16 (1998) 364-369
16. Nestle F.O., Alijagic S., Gilliet M., Sun Y., Grabbe S., Dummer R., Burg G., and Schadendorf D. Vaccination of melanoma patients with peptide- or tumour lysate-pulsed dendritic cells. Nat Med 4 (1998) 328-332
17. Nisi K.W., Foote R.L., Bonner J.A., and McCaffrey T.V. Adjuvant radiotherapy for squamous cell carcinoma of the tongue base: improved local-regional disease control compared with surgery alone. Int J Radiat Oncol Biol Phys 41 (1998) 371-377
18. Sallusto F., and Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumour necrosis factor alpha. J Exp Med 179 (1994) 1109-1118
19. Schuler G., and Steinman R.M. Dendritic cells as adjuvants for immune-mediated resistance to tumours. J Exp Med 186 (1997) 1183-1187
20. Schwartz M. A biomathematical approach to clinical tumour growth. Cancer 14 (1961) 1272-1294
21. Soares M.M., Mehta V., and Finn O.J. Three different vaccines based on the 140-amino acid MUC1 peptide with seven tandemly repeated tumour-specific epitopes elicit distinct immune effector mechanisms in wild-type versus MUC1-transgenic mice with different potential for tumour rejection. J Immunol 166 (2001) 6555-6563
22. Song M., Chen F.J., Zeng Z.Y., Wu G.H., Wei M.W., Guo Z.M., Zhang Q., and Yang A.K. Clinical value of inducing chemotherapy for patients with advanced tongue cancer. Ai Zheng 21 (2002) 68-70
23. Xia J., Tanaka Y., Koido S., Liu C., Mukherjee P., Gendler S.J., and Gong J. Prevention of spontaneous breast carcinoma by prophylactic vaccination with dendritic/tumour fusion cells. J Immunol 170 (2003) 1980-1986
24. Yamanaka R., Abe T., Yajima N., Tsuchiya N., Homma J., Kobayashi T., Narita M., Takahashi M., and Tanaka R. Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial. Br J Cancer 89 (2003) 1172-1179
25. Zhou L.J., and Tedder T.F. Human blood dendritic cells selectively express CD83, a member of the immunoglobulin superfamily. J Immunol 154 (1995) 3821-3835